Efficiency of Coupling Targeted Temperature Management to Brain Temperature in Severe Brain Injury

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-27

Study Completion Date

2024-04-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In severe brain-injured patients, it is recommended to strictly control the fever in order to limit brain damage (objective of neuroprotection) via the targeted temperature management (TTM). In the guidelines, the target temperature is the systemic temperature, just for practical reasons (brain temperature not being monitored in most polyvalent ICU). However, in NICU, the brain temperature is monitored routinely via the Intra-Cerebral Pressure (ICP) sensor. Since in the febrile brain-injured patients the objective of the TTM is neuroprotection, it would be more appropriate to target temperature control over the cerebral temperature.

The objective of this study is to evaluate the efficacy of TTM directly coupled to the brain temperature.

Adult patients with brain injury requiring ICP monitoring (Pressio 2, Sophysa France) and fever requiring TTM (cerebral greater than or equal to 38.5 °C) will be enrolled. The TTM will be carried out according to the usual methods of the investigator's service: external cooling devices coupled with cerebral temperature (Artic Sun, Bard France), including two phases: the cooling phase (H0 to H3) and the maintenance phase (from H3 to the end of the cooling).

Two groups will be formed. In the interventional group, coupling of the TTM will be carried out to the cerebral temperature. In the control group, coupling of the TTM will be carried out to the systemic temperature measured at the bladder site.

The primary outcome will be the percentage of time during which the cerebral temperature will be measured within recommended target temperature range (i.e. 36 to 37 °C) during the maintenance phase (H3 to H12): comparison of averages. Cerebral hemodynamic parameters (ICP, transcranial doppler, and brain tissue oxygen partial pressure if available) will also be collected, in order to be correlated with the delta temperature (cerebral temperature minor systemic temperature).

No medical device will be put in place specifically for the need of the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Targeted Temperature Management on Cerebral Autoregulation in Patients With Neurocritical Diseases

NCT04728438

Ischemic Stroke Subarachnoid Hemorrhage, Aneurysmal Sepsis +3 more

UNKNOWN

Normothermia Protocol for Traumatic Brain Injury Patients

NCT01354509

Traumatic Brain Injury

UNKNOWN

Accuracy of Zero Heat Flux Cutaneous Temperature in Intensive Care Adults

NCT02931227

Continuous Non Invasive Cutaneous Temperature Zero Heat Flux Method Esophageal Temperature +2 more

COMPLETED NA

Impact of Fever Prevention in Brain Injured Patients

NCT02996266

Fever Ischemic Stroke Intracerebral Hemorrhage +1 more

TERMINATED NA

Hypothermia for Encephalopathy in Low Income Countries-Feasibilty

NCT01760629

Neonatal Encephalopathy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brain Injuries

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

* experimental group: CCT (cerebral temperature target) performed by the external cooling device on the TC measured by the PIC/TC sensor (PIC:intracranial pressure)
* control group: CCT performed by the external cooling device on the TS, measured by a bladder sensor (coupled to the vesal probe, according to the standard service protocol).

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cerebral temperature target

CCT performed by the external cooling device with cerebral temperature target, measured by a intracranial sensor (coupled to the intracranial pressure device)

Group Type EXPERIMENTAL

external cooling with the xxxxx device

Intervention Type DEVICE

external cooling with the xxxxx device

Systemic temperature target

CCT performed by the external cooling device with systemic temperature target, measured by a bladder sensor (coupled to the vesal probe, according to the standard service protocol).

Group Type ACTIVE_COMPARATOR

external cooling with the xxxxx device

Intervention Type DEVICE

external cooling with the xxxxx device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

external cooling with the xxxxx device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients 18 years of age or older
* hospitalized patient in neuro-resuscitation with peak monitoring with cerebral temperature measurement by an intra-parenchymal sensor (Sophysa®)
* patient in hyperthermia (TC ≥ 38.5 °c) and in a situation of brain pain